WuXi XDC Out-Licenses WuXiTecan-2 Linker-Payload Technology to Ona Therapeutics to Accelerate ADC Development

September 20, 2026

PR Newswire China

Overview

WuXi XDC announced the out-licensing of its innovative WuXiTecan-2 linker-payload technology platform to Ona Therapeutics, a Spanish biotechnology company, to advance novel Antibody-Drug Conjugate (ADC) research and development. This licensing agreement is expected to accelerate Ona Therapeutics’ development of next-generation ADCs for its solid tumor pipeline. WuXiTecan-2 combines a stable linker with a potent topoisomerase I inhibitor payload, offering potential for an enhanced therapeutic index and broader applicability across various cancer types.

In Depth

Key Findings: WuXi XDC Licenses Innovative ADC Technology to Ona Therapeutics

WuXi XDC has announced an out-licensing agreement for its proprietary, next-generation Antibody-Drug Conjugate (ADC) linker-payload technology platform, WuXiTecan-2, to Ona Therapeutics, a biotechnology company based in Spain. This strategic collaboration aims to accelerate Ona Therapeutics’ research and development of novel ADC candidates in the solid tumor therapeutic area. The WuXiTecan-2 platform is engineered to deliver a high-potency cytotoxic payload via a highly stable linker, designed to provide ADCs with an improved therapeutic index and a superior safety profile.

Technical & Clinical Details: Superiority of the WuXiTecan-2 Platform

The WuXiTecan-2 platform integrates a topoisomerase I inhibitor-based payload with a novel, highly selective, and stable linker. This linker is optimized for high stability in circulation, ensuring minimal off-target toxicity, while efficiently releasing the payload within tumor cells to exert potent cytotoxic effects. Compared to existing Tecan-based payloads, WuXiTecan-2 is reported to offer improved pharmacokinetic properties and a wider therapeutic window. Leveraging this platform, Ona Therapeutics aims to develop new treatments for refractory solid tumors, addressing existing challenges such as resistance mechanisms and toxicity profiles associated with current ADCs.

Background & Industry Context: ADC Market Competition and Platform Importance

Antibody-Drug Conjugates are rapidly evolving as one of the most promising modalities in cancer therapy. Their efficacy is profoundly influenced by the judicious selection and combination of the antibody, linker, and payload components. Innovations in linker and payload technologies are particularly crucial for enhancing the therapeutic index of ADCs and developing safer, more effective drugs. WuXi XDC is a leading global ADC Contract Development and Manufacturing Organization (CDMO), and its technology platforms are highly attractive to pharmaceutical and biotechnology companies worldwide. This licensing agreement clearly demonstrates the competitive strength of WuXi XDC’s technology and its capability to augment external partners’ pipelines.

Future Outlook: Advancing Solid Tumor Therapy and Expanding Global Partnerships

Ona Therapeutics plans to utilize the WuXiTecan-2 technology to develop breakthrough therapies for patients with solid tumors that are resistant to current cancer treatments. This collaboration highlights the potential of evolving ADC technologies to offer new hope to cancer patients, with tangible results expected as Ona Therapeutics’ pipeline advances into clinical stages. For WuXi XDC, this licensing agreement is a significant step in globally expanding its technology platform and providing innovative ADC solutions to a broader range of partners. Such technology licensing and partnerships are key drivers of innovation within the cancer drug development ecosystem.

Source: https://www.prnewswire.com/news-releases/wuxi-xdc-out-licenses-wuxitecan-2-payload-linker-technology-platform-to-ona-therapeutics-to-advance-novel-adc-research-and-development-302881776.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.